Otonomy Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update

Otonomy (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today reported financial results for the fourth quarter and year ended December 31, 2017 and provided an update on its corporate activities and product pipeline. The company will host a conference call and webcast today at 4:30 p.m. EST to discuss recent highlights and financial results.

As quoted in the press release:

“The fourth quarter of 2017 was a transformational period for Otonomy as we repositioned the company to focus on advancing our broad pipeline of development programs including OTIVIDEX for Ménière’s disease, OTO-313 for tinnitus, and multiple programs for hearing loss,” said Dr. Weber. “Furthermore, our recent positive regulatory updates position us for a very productive year ahead. Approval of OTIPRIO for AOE is an important accomplishment that will support our ongoing commercial partnering discussions, and the recent FDA feedback on OTIVIDEX provides clarity on our path forward for registration in Ménière’s disease.”

Click here to read the full press release.